|By Marketwired .||
|July 7, 2014 01:16 PM EDT||
TORONTO, ONTARIO -- (Marketwired) -- 07/07/14 -- Arch Biopartners Inc ("Arch" or the "Company")(CNSX:ACH)(OTCBB:FOIFF) announced today it has raised $200,200 via a non-brokered private placement of 715,000 Units at a price of $0.28 per Unit. Each Unit comprises of one common share and one common share purchase warrant. Each warrant allows the holder to purchase an additional common share at $0.50 cents during the 24 month period following the close of the private placement. The proceeds will be used for the Company's working capital and general corporate purposes. The common shares and any common shares issued from the exercise of the warrants will be subject to a hold period of 4 months from the closing date.
The Company now has 50,349,679 common shares outstanding.
About Arch Biopartners
Arch Biopartners is a portfolio based biotechnology company established to develop new products and technology for sale to pharmaceutical and industrial companies.
For more information on the Company, please consult the other public documents filed on SEDAR at www.sedar.com.
The Company's website address is: www.archbiopartners.com.
All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.
The CNSX has not reviewed and does not accept responsibility for the adequacy of this release.
Dec. 6, 2016 01:00 AM EST Reads: 1,842
Dec. 6, 2016 12:45 AM EST Reads: 838
Dec. 6, 2016 12:30 AM EST Reads: 3,884
Dec. 6, 2016 12:30 AM EST Reads: 1,194
Dec. 6, 2016 12:30 AM EST Reads: 4,580
Dec. 6, 2016 12:00 AM EST Reads: 878
Dec. 5, 2016 11:45 PM EST Reads: 4,299
Dec. 5, 2016 10:45 PM EST Reads: 2,075
Dec. 5, 2016 10:30 PM EST Reads: 1,055
Dec. 5, 2016 10:30 PM EST Reads: 981
Dec. 5, 2016 09:00 PM EST Reads: 4,960
Dec. 5, 2016 08:45 PM EST Reads: 508
Dec. 5, 2016 07:45 PM EST Reads: 2,229
Dec. 5, 2016 07:45 PM EST Reads: 2,092
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain. In this power panel at @...
Dec. 5, 2016 07:15 PM EST Reads: 403